[1] Ferri C P, Prince M, Brayne C, et al. Global prevalence of dementia:a Delphi consensus study[J]. Lancet, 2005, 366(9503):2112-2117. [2] Chan K Y, Wang W, Wu J J, et al. Epidemiology of Alzheimer's disease and other forms of dementia in China, 1990-2010:a systematic review and analysis[J]. Lancet, 2013, 381(9882):2016-2023. [3] Li W, Yu J, Liu Y, et al. Elevation of brain magnesium prevents synaptic loss and reverses cognitive deficits in Alzheimer inverted question marks disease mouse model[J]. Mol Brain, 2014, 7(1):65. [4] Louise W. Treatment for Alzheimer's disease:has anything changed?[J]. Aust Prescr, 2015, 38(2):60-63. [5] 刘鹏, 朱琳, 纪雪飞, 等. 文冠果壳苷对APP/PS1转基因小鼠突触可塑性的作用及其机制研究[J]. 神经药理学报, 2017, 7(2):37. [6] Chiara C, Carlotta F, Elisa C, et al. Synaptic dysfunction in alzheimer's disease and glaucoma:from common degenerative mechanisms toward neuroprotection[J]. Front Cell Neurosci, 2017,11:53. [7] 杨翠翠,包训杰,张丽,等. 山茱萸环烯醚萜苷对APP/PS1/Tau三转基因小鼠脑内病理变化的影响[J]. 首都医科大学学报,2019, 40(4):588-595. [8] Cees M, Verwey N A, Van d F W M, et al. Amyloid-β(1-42), total tau, and phosphorylated tau as cerebrospinal fluid biomarkers for the diagnosis of Alzheimer disease[J]. Clin Chem, 2009, 56(2):248-253. [9] Xylaki1 M, Atzler1 B, Outeiro T F. Epigenetics of the synapse in neurodegeneration[J]. Curr Neurol Neurosci Rep, 2019, 19(10):72. [10] 王丽, 焦劲松, 刘尊敬, 等. APP/PS-1/tau三转基因阿尔茨海默病模型小鼠早期认知功能研究[J]. 中国现代神经疾病杂志, 2015,15(5):406-410. [11] Reddy P H, Mani G, Park B S, et al. Differential loss of synaptic proteins in Alzheimer's disease:implications for synaptic dysfunction[J]. J Alzheimers Dis, 2005, 7(2):103-117. [12] Leuba G, Walzer C, Vernay A, et al. Postsynaptic density protein PSD-95 expression in Alzheimer's disease and okadaic acid induced neuritic retraction[J]. Neurobiol Dis, 2008, 30(3):408-419. [13] Koffie R M, Hyman B T, Spires-Jones T L. Alzheimer's disease:synapses gone cold[J]. Mol Neurodegener, 2011, 6(1):63. [14] Song S H, Augustine G J. Synapsin isoforms and synaptic vesicle trafficking[J]. Mol Cells, 2015, 38(11):936-940. [15] Gouras G K. Aβ42 and tau pathologies are related and begin at synapses[J]. Alzheimer's Dement, 2010, 6(4):S148-S148. [16] Song J M, DiBattista A M, Sung Y M, et al. A tetra(ethylene glycol) derivative of benzothiazole aniline ameliorates dendritic spine density and cognitive function in a mouse model of Alzheimer's disease[J]. Exp Neurol, 2014, 252:105-113. [17] Ye M, Chung H, An Y H, et al. Standardized herbal formula PM012 decreases cognitive impairment and promotes neurogenesis in the 3×Tg AD mouse model of Alzheimer's disease[J]. Mol Neurobiol, 2016, 53(8):5401-5412. [18] Ye M, Moon J, Yang J, et al. The standardized Lycium chinense fruit extract protects against Alzheimer's disease in 3xTg-AD mice[J]. J Ethnopharmacol, 2015, 172:85-90. [19] 王利利, 纳鑫, 朱小南, 等. Tau/APP/PS1三转基因小鼠模型的建立及生物学特征[J]. 中国应用生理学杂志, 2012, 28(4):294-297. [20] Jankowsky J L, Zheng H. Practical considerations for choosing a mouse model of Alzheimer's disease[J]. Mol Neurodegener, 2017, 12(1):89. [21] Cortès-Saladelafont E, Lipstein N, García-Cazorla À. Presynaptic disorders:a clinical and pathophysiological approach focused on the synaptic vesicle[J]. J Inherit Metab Dis, 2018, 41(4):1-15. [22] 曹君利, 丁海雷, 杨国栋, 等. 囊泡胞吐机制及与其相关的神经元可塑性[J]. 生命科学, 2003,15(5):283-288. [23] 张拯,杨娟娇,孙琪,等.不同强度电针治疗对血管性痴呆大鼠学习记忆功能及海马CA1区β淀粉样蛋白1-40表达的影响[J].中国脑血管病杂志,2017,14(6):321-325. [24] Mirza, F J, Zahid, S. The role of synapsins in neurological disorders[J]. Neurosci Bull, 2017, 34(2):349-358. |